Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.63 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | WHR1 | P49842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4990186 | 0.99 | HTR1B (0.62) | HTR1BGPR35ALOX15ALDH1A1KDM4E | |
| SCHEMBL4991548 | 0.90 | HTR1B (0.65) | HTR1BGPR35ALDH1A1KDM4EHPGD | |
| SCHEMBL14370189 | 0.78 | HTR1B (1.00) | HTR1BALDH1A1KDM4ETSHRHTR1A | |
| SCHEMBL6622649 | 0.76 | HTR1B (0.49) | HTR1BALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL4986419 | 0.75 | HTR1B (0.65) | HTR1BGPR35ALDH1A1KDM4ETSHR | |
| SCHEMBL4985894 | 0.74 | HTR1B (0.65) | HTR1BGPR35ALDH1A1KDM4EHTR1A | |
| SCHEMBL5320835 | 0.74 | KDM4E (0.47) | HTR1BGPR35ALOX15ALDH1A1KDM4E | |
| SCHEMBL4988701 | 0.69 | HTR1B (0.42) | HTR1BGPR35ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL6080168 | 0.69 | HTR6 (0.45) | HTR1BALDH1A1KDM4EHTR1AHTR1D | |
| SCHEMBL6593434 | 0.68 | ALDH1A1 (0.49) | HTR1BALDH1A1TSHRHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | HTR1B 2/4885GPR35 113/4885ALOX15 1121/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | HTR1B 1/4885GPR35 326/4885ALOX15 1997/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | HTR1B 3/4885GPR35 251/4885ALOX15 734/4885 |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | HTR1B 3/4885GPR35 204/4885ALOX15 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.